Stockscreener 앱 받기
109.55
0.23%
0.25
시간 외 거래:
110.98
1.43
+1.31%
전일 마감가:
$109.30
열려 있는:
$108.69
하루 거래량:
3.23M
Relative Volume:
0.90
시가총액:
$19.95B
수익:
$381.03M
순이익/손실:
$-1.01B
주가수익비율:
-18.41
EPS:
-5.95
순현금흐름:
$-789.25M
1주 성능:
+0.79%
1개월 성능:
+13.95%
6개월 성능:
+37.02%
1년 성능:
+52.56%
1일 변동 폭
$107.07
$109.88
1주일 범위
$106.54
$113.10
52주 변동 폭
$60.40
$113.10
Insmed Inc Stock (INSM) Company Profile
명칭
Insmed Inc
전화
908-977-9900
주소
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
INSM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
109.55 | 21.13B | 381.03M | -1.01B | -789.25M | -5.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-13 | 개시 | Jefferies | Buy |
| 2025-02-25 | 개시 | RBC Capital Mkts | Outperform |
| 2024-04-23 | 개시 | Truist | Buy |
| 2024-02-15 | 개시 | Wolfe Research | Outperform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-20 | 재개 | JP Morgan | Overweight |
| 2023-07-26 | 개시 | Guggenheim | Buy |
| 2022-12-09 | 개시 | Mizuho | Buy |
| 2022-12-07 | 개시 | Barclays | Overweight |
| 2022-11-18 | 개시 | BofA Securities | Buy |
| 2022-04-27 | 개시 | Goldman | Buy |
| 2021-12-06 | 개시 | JP Morgan | Overweight |
| 2021-10-19 | 재개 | Monness Crespi & Hardt | Buy |
| 2021-10-19 | 재개 | Morgan Stanley | Overweight |
| 2021-10-08 | 개시 | Cantor Fitzgerald | Overweight |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-10-12 | 재개 | Stifel | Buy |
| 2019-09-03 | 개시 | Goldman | Buy |
| 2019-04-09 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-15 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-01-17 | 업그레이드 | Goldman | Neutral → Buy |
| 2019-01-02 | 개시 | Canaccord Genuity | Buy |
| 2018-08-06 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2018-07-23 | 개시 | Goldman | Neutral |
| 2018-04-23 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2018-03-21 | 개시 | Morgan Stanley | Overweight |
| 2018-01-18 | 개시 | Credit Suisse | Neutral |
| 2017-09-05 | 재확인 | Evercore ISI | Outperform |
| 2017-08-17 | 개시 | Evercore ISI | Outperform |
| 2017-07-11 | 개시 | Robert W. Baird | Outperform |
| 2016-03-15 | 개시 | Stifel | Buy |
| 2015-11-09 | 다운그레이드 | UBS | Buy → Neutral |
| 2015-10-06 | 재확인 | H.C. Wainwright | Buy |
| 2015-06-09 | 개시 | Citigroup | Neutral |
| 2014-03-26 | 재확인 | HC Wainwright | Buy |
모두보기
Insmed Inc 주식(INSM)의 최신 뉴스
Strategic Implications of Insmed's Lock-Up Expiry and $650M Equity Raise on Shareholder Value and Market Position - AInvest
Insmed's Post-Lock-Up RSU Liquidity and Market Implications - AInvest
Will Insmed Incorporated bounce back from current support3-Year Equity Summary With Setup Insights - Newser
Insmed Incorporated (NASDAQ:INSM) Q2 2025 Earnings Call Transcript - Insider Monkey
Real time scanner hits for Insmed Incorporated explainedBollinger Band Squeeze and Expansion Analysis - Newser
H.C. Wainwright Maintains Buy Rating on Insmed with $120 Price Target - AInvest
Insmed's $350M Trade Ranks 273rd as High-Volume Strategy Generates 166% Alpha - AInvest
Insmed's Q2 net loss reaches $322M, but shares surge 68% amidst revenue guidance and Russell index inclusion. - AInvest
Insmed (INSM) Reports Increased Losses But Reiterates 2025 Revenue Guidance - Yahoo Finance
Insmed stock price target raised to $120 from $108 at RBC Capital - Investing.com Australia
UBS Adjusts Price Target on Insmed to $133 From $124, Maintains Buy Rating - MarketScreener
A Quick Look at Today's Ratings for Insmed(INSM.US), With a Forecast Between $111.26 to $135 - 富途牛牛
RBC Raises Price Target on Insmed to $120 From $108, Keeps Outperform Rating - MarketScreener
Insmed price target raised to $133 from $124 at UBS - TipRanks
Insmed: Q2 Earnings Snapshot - Connecticut Post
Insmed Reports Q2 Earnings with 19% ARIKAYCE Revenue Growth and Positive TPIP Study Results - AInvest
Insmed Inc (INSM) Q2 2025 Earnings Call Highlights: Strong Finan - GuruFocus
Insmed Reports Strong Growth and Strategic Advances - TipRanks
Decoding Insmed Inc (INSM): A Strategic SWOT Insight - GuruFocus
Insmed Sets $405M-$425M ARIKAYCE Revenue Target as Brensocatib Launch Approaches and Pipeline Advances - AInvest
Insmed's Q2 2025: Key Contradictions in Bronchiectasis Strategy, Pricing, and Market Access - AInvest
Insmed stock price target raised to $129 by Jefferies ahead of PDUFA - Investing.com Australia
Insmed Affirms 2025 Global Arikayce Revenue Target of $405M-$425M, Below Consensus Estimate of $466.61M - AInvest
Insmed Q2 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Insmed Q2 2025 sees revenue beat, stock dips - Investing.com Australia
Insmed Inc reports results for the quarter ended June 30Earnings Summary - TradingView
$100 Invested In Insmed 10 Years Ago Would Be Worth This Much Today - 富途牛牛
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update - Insmed Incorporated Investor Relations
Insmed (INSM) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Insmed Q2 2025 slides reveal 19% revenue growth amid clinical pipeline advances - Investing.com Canada
Insmed Inc. shares fall 1.53% premarket despite Q2 revenue beating estimates. - AInvest
Insmed Reiterates ARIKAYCE Revenue Guidance for 2025 - AInvest
Insmed (INSM) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Insmed Q2 Earnings: $321.7M Loss, Misses Analyst ForecastsNews and Statistics - IndexBox
Insmed Inc (INSM) Surpasses Q2 2025 Revenue Estimates with $107. - GuruFocus
Insmed earnings missed by $0.40, revenue topped estimates - Investing.com Canada
Insmed Q2 Loss Narrows, Revenue Rises - MarketScreener
Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update | INSM Stock News - GuruFocus
Insmed Q2 Revenue Up 19%, Exceeds Expectations - AInvest
FEAM releases new Fort Cady PFS, advancing boron project plans | INSM SEC FilingForm 10-Q - Stock Titan
Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025 - Eastern Progress
INSMED Inc Executives Make Significant Stock Purchases and Sales - AInvest
JPMorgan Chase & Co. Increases Stake in Insmed Inc. - GuruFocus
Insmed INSM Q2 2025 Earnings Preview Upside Potential on Promised Revenue Growth - AInvest
Insmed (INSM) Q2 Earnings Preview: What You Should Know Beyond the Headline Estimates - Yahoo Finance
Insmed Surges 2 35 on Pipeline Breakthroughs and Capital Restructuring Despite Ranking 449th in Daily Liquidity - AInvest
October 17th Options Now Available For Insmed (INSM) - Nasdaq
Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas - The Globe and Mail
Price Floor Holding on Insmed Incorporated — Rebound PossibleTop Performing Stock Insights Released Daily - metal.it
Should I hold or sell Insmed Incorporated stock in 2025Discover high-return stocks for your portfolio - Jammu Links News
How volatile is Insmed Incorporated stock compared to the marketUnlock powerful stock screening tools today - Jammu Links News
Insmed Inc (INSM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.10%
3.39%
자본화:
|
볼륨(24시간):